^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAS3351

    i
    Other names: TAS3351, TAS 3351, TAS-3351
    Company:
    Otsuka
    Drug class:
    EGFR inhibitor
    Related drugs:
    5d
    A Study of TAS3351 in NSCLC Patients With EGFRmt (clinicaltrials.gov)
    P1, N=18, Terminated, Taiho Oncology, Inc. | Phase classification: P1/2 --> P1
    Phase classification • First-in-human
    |
    TAS3351
    9ms
    A Study of TAS3351 in NSCLC Patients With EGFRmt (clinicaltrials.gov)
    P1/2, N=18, Terminated, Taiho Oncology, Inc. | N=200 --> 18
    Enrollment change
    |
    TAS3351
    10ms
    A Study of TAS3351 in NSCLC Patients With EGFRmt (clinicaltrials.gov)
    P1/2, N=200, Terminated, Taiho Oncology, Inc. | Trial completion date: Dec 2027 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Mar 2025; Strategic decision, not based on safety concerns
    Trial completion date • Trial termination • Trial primary completion date
    |
    TAS3351
    over2years
    A Study of TAS3351 in NSCLC Patients With EGFRmt (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Taiho Oncology, Inc.
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR C797S
    |
    TAS3351
    almost3years
    A Study of TAS3351 in NSCLC Patients With EGFRmt (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Taiho Oncology, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR C797S
    |
    TAS3351